|
1
|
Brizel DM, Scully SP, Harrelson JM,
Layfield LJ, Bean JM, Prosnitz LR and Dewhirst MW: Tumor
oxygenation predicts for the likelihood of distant metastases in
human soft tissue sarcoma. Cancer Res. 56:941–943. 1996.PubMed/NCBI
|
|
2
|
Brizel DM, Sibley GS, Prosnitz LR, Scher
RL and Dewhirst MW: Tumor hypoxia adversely affects the prognosis
of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys.
38:285–289. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vaupel P, Thews O, Mayer A, Höckel S and
Höckel M: Oxygenation status of gynecologic tumors: What is the
optimal hemoglobin level? Strahlenther Onkol. 178:727–731. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duong HS, Le AD, Zhang Q and Messadi DV: A
novel 3-dimensional culture system as an in vitro model for
studying oral cancer cell invasion. Int J Exp Pathol. 86:365–374.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Petrella BL, Lohi J and Brinckerhoff CE:
Identification of membrane type-1 matrix metalloproteinase as a
target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau
renal cell carcinoma. Oncogene. 24:1043–1052. 2005. View Article : Google Scholar
|
|
6
|
Maity A and Solomon D: Both increased
stability and transcription contribute to the induction of the
urokinase plasminogen activator receptor (uPAR) message by hypoxia.
Exp Cell Res. 255:250–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Montuori N, Mattiello A, Mancini A,
Santoli M, Taglialatela P, Caputi M, Rossi G and Ragno P:
Urokinase-type plasminogen activator up-regulates the expression of
its cellular receptor through a post-transcriptional mechanism.
FEBS Lett. 508:379–384. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL: Relation
of hypoxia inducible factor 1 alpha and 2 alpha in operable
non-small cell lung cancer to angiogenic/molecular profile of
tumours and survival. Br J Cancer. 85:881–890. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semenza GL: Hypoxia-inducible factors in
physiology and medicine. Cell. 148:399–408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fukuda R, Zhang H, Kim JW, Shimoda L, Dang
CV and Semenza GL: HIF-1 regulates cytochrome oxidase subunits to
optimize efficiency of respiration in hypoxic cells. Cell.
129:111–122. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nishi H, Nakada T, Kyo S, Inoue M, Shay JW
and Isaka K: Hypoxia-inducible factor 1 mediates upregulation of
telomerase (hTERT). Mol Cell Biol. 24:6076–6083. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McNally SJ, Harrison EM, Ross JA, Garden
OJ and Wigmore SJ: Curcumin induces heme oxygenase 1 through
generation of reactive oxygen species, p38 activation and
phosphatase inhibition. Int J Mol Med. 19:165–172. 2007.
|
|
13
|
Kim J, Yu W, Kovalski K and Ossowski L:
Requirement for specific proteases in cancer cell intravasation as
revealed by a novel semiquantitative PCR-based assay. Cell.
94:353–362. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamano M, Fujii H, Takagaki T, Kadowaki N,
Watanabe H and Shirai T: Genetic progression and divergence in
pancreatic carcinoma. Am J Pathol. 156:2123–2133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lal A, Peters H, St Croix B, Haroon ZA,
Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ and
Riggins GJ: Transcriptional response to hypoxia in human tumors. J
Natl Cancer Inst. 93:1337–1343. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koong AC, Denko NC, Hudson KM, Schindler
C, Swiersz L, Koch C, Evans S, Ibrahim H, Le QT, Terris DJ, et al:
Candidate genes for the hypoxic tumor phenotype. Cancer Res.
60:883–887. 2000.PubMed/NCBI
|
|
17
|
Graham CH, Forsdike J, Fitzgerald CJ and
Macdonald-Goodfellow S: Hypoxia-mediated stimulation of carcinoma
cell invasiveness via upregulation of urokinase receptor
expression. Int J Cancer. 80:617–623. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mazar AP, Henkin J and Goldfarb RH: The
urokinase plasminogen activator system in cancer: Implications for
tumor angiogenesis and metastasis. Angiogenesis. 3:15–32. 1999.
View Article : Google Scholar
|
|
19
|
Bauer TW, Liu W, Fan F, Camp ER, Yang A,
Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, et al:
Targeting of urokinase plasminogen activator receptor in human
pancreatic carcinoma cells inhibits c-Met- and insulin-like growth
factor-I receptor-mediated migration and invasion and orthotopic
tumor growth in mice. Cancer Res. 65:7775–7781. 2005.PubMed/NCBI
|
|
20
|
Reuning U, Sperl S, Kopitz C, Kessler H,
Krüger A, Schmitt M and Magdolen V: Urokinase-type plasminogen
activator (uPA) and its receptor (uPAR): Development of antagonists
of uPA/uPAR interaction and their effects in vitro and in vivo.
Curr Pharm Des. 9:1529–1543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Degryse B, Sier CF, Resnati M, Conese M
and Blasi F: PAI-1 inhibits urokinase-induced chemotaxis by
internalizing the urokinase receptor. FEBS Lett. 505:249–254. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramont L, Pasco S, Hornebeck W, Maquart FX
and Monboisse JC: Transforming growth factor-beta1 inhibits tumor
growth in a mouse melanoma model by down-regulating the plasminogen
activation system. Exp Cell Res. 291:1–10. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fox SB, Taylor M, Grøndahl-Hansen J,
Kakolyris S, Gatter KC and Harris AL: Plasminogen activator
inhibitor-1 as a measure of vascular remodelling in breast cancer.
J Pathol. 195:236–243. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Büchler P, Reber HA, Tomlinson JS,
Hankinson O, Kallifatidis G, Friess H, Herr I and Hines OJ:
Transcriptional regulation of urokinase-type plasminogen activator
receptor by hypoxia-inducible factor 1 is crucial for invasion of
pancreatic and liver cancer. Neoplasia. 11:196–206. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Montagne M, Naud JF, McDuff FO and Lavigne
P: Toward the elucidation of the structural determinants
responsible for the molecular recognition between Mad1 and Max.
Biochemistry. 44:12860–12869. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu J, Banerjee A and Goss DJ: Assembly of
b/HLH/z proteins c-Myc, Max, and Mad1 with cognate DNA: Importance
of protein-protein and protein-DNA interactions. Biochemistry.
44:11855–11863. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Semov A, Marcotte R, Semova N, Ye X and
Wang E: Microarray analysis of E-box binding-related gene
expression in young and replicatively senescent human fibroblasts.
Anal Biochem. 302:38–51. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vervoorts J and Lüscher B: DNA binding of
Myc/Max/Mad network complexes to oligonucleotides containing two E
box elements: c-Myc/Max heterodimers do not bind DNA cooperatively.
Biol Chem. 380:1121–1126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koshiji M, Kageyama Y, Pete EA, Horikawa
I, Barrett JC and Huang LE: HIF-1alpha induces cell cycle arrest by
functionally counteracting Myc. EMBO J. 23:1949–1956. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Powis G and Kirkpatrick L: Hypoxia
inducible factor-1alpha as a cancer drug target. Mol Cancer Ther.
3:647–654. 2004.PubMed/NCBI
|
